The strong market consensus against a hantavirus vaccine becoming available in 2026 reflects the early-stage status of all candidates, with no candidates advancing beyond Phase 1 trials or securing regulatory approval in the US, Europe, or Latin America. Preclinical mRNA efforts, including Moderna collaborations and UTMB single-dose Andes virus candidates, have shown protective antibodies and 100% efficacy in animal models as of mid-2026, yet human safety and immunogenicity data remain limited to small Phase 1 studies like the ongoing UK MVA-Hanta trial. Strain diversity across hantaviruses, the rarity of cases complicating large efficacy trials, and the absence of Phase 3 data or emergency-use pathways further support trader views. An unexpected major outbreak could accelerate timelines, though current surveillance and funding constraints make this improbable before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% probabilità
$131,745 Vol.
$131,745 Vol.
31 dic 2026
6% probabilità
$131,745 Vol.
$131,745 Vol.
31 dic 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The strong market consensus against a hantavirus vaccine becoming available in 2026 reflects the early-stage status of all candidates, with no candidates advancing beyond Phase 1 trials or securing regulatory approval in the US, Europe, or Latin America. Preclinical mRNA efforts, including Moderna collaborations and UTMB single-dose Andes virus candidates, have shown protective antibodies and 100% efficacy in animal models as of mid-2026, yet human safety and immunogenicity data remain limited to small Phase 1 studies like the ongoing UK MVA-Hanta trial. Strain diversity across hantaviruses, the rarity of cases complicating large efficacy trials, and the absence of Phase 3 data or emergency-use pathways further support trader views. An unexpected major outbreak could accelerate timelines, though current surveillance and funding constraints make this improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercato aperto: May 4, 2026, 10:39 AM ET
Volume
$131,745Data di fine
1 gen 2027Mercato aperto
May 4, 2026, 10:39 AM ETRisolutore
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The strong market consensus against a hantavirus vaccine becoming available in 2026 reflects the early-stage status of all candidates, with no candidates advancing beyond Phase 1 trials or securing regulatory approval in the US, Europe, or Latin America. Preclinical mRNA efforts, including Moderna collaborations and UTMB single-dose Andes virus candidates, have shown protective antibodies and 100% efficacy in animal models as of mid-2026, yet human safety and immunogenicity data remain limited to small Phase 1 studies like the ongoing UK MVA-Hanta trial. Strain diversity across hantaviruses, the rarity of cases complicating large efficacy trials, and the absence of Phase 3 data or emergency-use pathways further support trader views. An unexpected major outbreak could accelerate timelines, though current surveillance and funding constraints make this improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,745Data di fine
1 gen 2027Mercato aperto
May 4, 2026, 10:39 AM ETRisolutore
0x65070BE91...The strong market consensus against a hantavirus vaccine becoming available in 2026 reflects the early-stage status of all candidates, with no candidates advancing beyond Phase 1 trials or securing regulatory approval in the US, Europe, or Latin America. Preclinical mRNA efforts, including Moderna collaborations and UTMB single-dose Andes virus candidates, have shown protective antibodies and 100% efficacy in animal models as of mid-2026, yet human safety and immunogenicity data remain limited to small Phase 1 studies like the ongoing UK MVA-Hanta trial. Strain diversity across hantaviruses, the rarity of cases complicating large efficacy trials, and the absence of Phase 3 data or emergency-use pathways further support trader views. An unexpected major outbreak could accelerate timelines, though current surveillance and funding constraints make this improbable before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti